Pharma RSS Digest - 2026-05-16

Overview

The pharma landscape this session reflects a sector in transition, with Alzheimer's disease research leading the narrative. Biogen's tau-targeting antisense oligonucleotide diranersen delivered mixed Phase 2 results—missing its primary endpoint while posting secondary signals that kept the program alive. The broader Alzheimer's pipeline is visibly diversifying, with three-quarters of current trials now pursuing non-amyloid, non-tau pathways, suggesting the field is maturing beyond its initial amyloid hypothesis bet. Meanwhile, smaller-cap immuno-oncology players like TuHURA Biosciences continue to access creative financing structures and regulatory designations that could reshape their development timelines. The tape is light with only three candidate stories, and one—Citius Pharmaceuticals—lacks sufficient detail for thorough coverage.

Key Developments

Biogen's Diranersen Misses Primary Endpoint but Generates Downstream Signals in Phase 2 CELIA Study

The ADDF clinical trial update

Biogen announced May 14 that its Phase 2 CELIA study evaluating diranersen—an antisense oligonucleotide targeting tau—in early Alzheimer's disease did not meet its primary endpoint, though specifics were not disclosed. Secondary outcomes showed reductions in tau burden and preliminary signals of slowed cognitive decline. The company plans to advance the asset into further trials despite the top-line miss. ADDF leadership characterized the results as an "encouraging signal" and a milestone toward combination therapies, noting the broader Alzheimer's pipeline is "becoming broader, deeper, and more ambitious." Diranersen represents the first therapy of its kind to reach this stage, offering early proof of concept for tau-targeting via antisense mechanism. A successful tau-targeted approach would enable combination strategies alongside existing anti-amyloid therapies. The field's shift toward precision medicine is underscored by the fact that 75% of current Alzheimer's trials target pathways beyond amyloid and tau—including inflammation, metabolic dysfunction, and oxidative stress. Full data presentation is scheduled for the Alzheimer's Association International Conference, July 12–16, 2026, in London.

TuHURA Biosciences clinical trial update

TuHURA Biosciences Secures $50M Credit Facility and Receives FDA Orphan Drug Designation for IFx-2.0

Citius Pharmaceuticals, Inc. funding update

TuHURA Biosciences reported first-quarter 2026 results alongside several corporate updates. The company entered a $50 million non-equity credit facility with its largest stockholder, bearing a 12% annual interest rate and maturing April 21, 2031, extending cash runway into 2028. The FDA granted Orphan Drug Designation for IFx-2.0 in stage IIB to IV cutaneous melanoma based on Phase 1 data demonstrating safety and clinical benefit in checkpoint inhibitor-refractory patients—a designation that qualifies for tax credits, study grants, and seven-year market exclusivity upon approval. Leadership additions include Craig Tendler, M.D. providing Chief Medical Officer-level strategic services while remaining on the board, and Amanda Garofalo as Senior Vice President of Clinical Operations. Cash stood at $6.3 million at quarter-end, with Q1 R&D expenses of $5.2 million. The company is advancing toward an FDA IND meeting for its TBS-2025 VISTA inhibitor in the first half of 2026 and initiating a Phase 1b/2 trial in molecularly defined AML subsets in the second half. Phase 3 enrollment for IFx-2.0 as an adjunct to Keytruda in first-line advanced Merkel Cell Carcinoma is targeted for completion in the second half of 2027.

Watchlist

• Full CELIA study data — Tau reductions and cognitive signals warrant close review once presented at AAIC 2026; clinical meaningfulness remains unconfirmed pending detailed disclosure. [link]
• TuHURA enrollment progress — Phase 3 accrual rates for IFx-2.0 in Merkel Cell Carcinoma will be a key catalyst read as the year progresses. [link]
• FDA IND outcome for TBS-2025 — VISTA inhibitor entering AML development represents a differentiated play; IND meeting outcome expected first half 2026.